TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00962390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03199339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Study: NCT04391894
Drug: ECF843
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular eye drop
Study: NCT00088998
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01271790
Drug: Copegus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study: NCT01271790
Drug: GS-9451 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching GS-9451 tablet QD
Study: NCT01271790
Drug: Copegus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
Study: NCT03538522
Drug: Placebo oral capsule QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of oral placebo capsule QD or 24 weeks
Study: NCT03319901
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of chemotherapy is administered
Study: NCT04431089
Drug: SHC014748M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
Study: NCT03202186
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule treatment
Study: NCT01198379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03332797
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
Study: NCT04227652
Drug: Ibuprofen administration
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
Study: NCT02289209
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
Study: NCT02353299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo single nighttime dose-1.5 hours
Study: NCT02353299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo single nighttime dose-4 hours
Study: NCT01178996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02349009
Drug: C-82 Topical Gel, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: active
Study: NCT02349009
Drug: C-82 Topical Gel, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03298542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to golimumab.
Study: NCT02960997
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02797067
Drug: indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg rectal indomethacin 30min before ESWL
Study: NCT00002951
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02281929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in three daily doses during 30 days
Study: NCT02281929
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
Study: NCT01182766
Drug: Placebo with brief behavioral enhancement therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03675776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (prefilled syringe, weekly IV administration).
Study: NCT03315091
Drug: Treatment A - AZD1775 administered under fasted conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
Study: NCT03315091
Drug: Treatment B - AZD1775 administered under fed conditions.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor.
Study: NCT00584740
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg
Study: NCT00584740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AIN457
Study: NCT01009281
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03860571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT01711671
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current approved standard of care
Study: NCT02212561
Drug: methotrexate/hydrocortisone/cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
Study: NCT02917928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
Study: NCT01591356
Drug: EphA2-targeting DOPC-encapsulated siRNA
Normalized name: DOPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00334828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo; intravenous infusion.
Study: NCT00004161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01056380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, twice daily with food for 5 days
Study: NCT03526874
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
Study: NCT03267303
Drug: TS-091 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally taken once daily for 3 weeks
Study: NCT02933827
Drug: ELIXCYTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose-derived stem cells (ADSCs)
Study: NCT03267303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally taken once daily for 3 weeks
Study: NCT02419469
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses.
Study: NCT02419469
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1.
Study: NCT02419469
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly.
Study: NCT02419469
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
Study: NCT01682512
Drug: Rituxan®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01682512
Drug: MabThera®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03366688
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
Study: NCT01704040
Drug: CNTO 3157 (healthy participants)
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
Study: NCT01704040
Drug: Placebo (healthy participants)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
Study: NCT01704040
Drug: Placebo (asthmatic patients)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
Study: NCT02953639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
Study: NCT03386240
Drug: Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of using Plus group (Triclosan-coated Sutures)
Study: NCT00407680
Drug: Intensive therapy Valsartan,Fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01920386
Drug: Tramadol hydrochloride/Acetaminophen Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01920386
Drug: Tramadol hydrochloride/Acetaminophen SR Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01456377
Drug: predinose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg for kg for 3 wekees
Study: NCT01456377
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: use a oral placebo
Study: NCT04079673
Drug: Intravenous patient controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
Study: NCT00373061
Drug: Xolair®
Approvals — FDA: no, EMA: no, PMDA: no
Description: This being an observational study, the study protocol does not specify any dose regimen.
Study: NCT04059367
Drug: NNC9204-1177
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
Study: NCT00770354
Drug: AS1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
Study: NCT01676259
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folfirinox or modified Folfirinox
Study: NCT00517257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet orally once daily for 24 weeks
Study: NCT01092065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsule to be taken bid for six weeks
Study: NCT01908972
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg/kg/day for 16weeks
Study: NCT02366975
Drug: Testosterone gel 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone gel 2% (50mg/die).
Study: NCT02435342
Drug: dalazatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
Study: NCT02435342
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, Subcutaneous injection twice per week for a total of 9 doses
Study: NCT00450385
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
Study: NCT00450385
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
Study: NCT01286831
Drug: [14C]GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200μg dose of \[14C\]GW642444 given on Day 1.
Study: NCT01415128
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Desipramine (50 mg) for 1 day
Study: NCT04132960
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HER2-antibody drug conjugate (ADC)
Study: NCT00005578
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005578
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03483246
Drug: Sham-transplantation Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum.
Study: NCT03679312
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Study: NCT03679312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study: NCT03395132
Drug: Fucicort® Lipid cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
Study: NCT03395132
Drug: Fucidin® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
Study: NCT03395132
Drug: Fucicort® Lipid cream vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
Study: NCT03586037
Drug: AD-2012 80mg
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-2012 80mg tablet
Study: NCT02585531
Drug: Hypertonic Saline 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours .
Study: NCT02585531
Drug: Epinephrine and Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours.
Study: NCT01150474
Drug: Placebo Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
Study: NCT02380066
Drug: Anyu Peibo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00675701
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00884663
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets and capsules
Study: NCT02901496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
Study: NCT01702181
Drug: OPA-15406
Normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
Study: NCT01702181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01862120
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
Study: NCT03368963
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03104699
Drug: AGEN2034
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 Monoclonal Antibody
Study: NCT01462435
Drug: Diclofenac Test (lower dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT01462435
Drug: Diclofenac Test (upper dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT01462435
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg Capsules
Study: NCT01462435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT00234936
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05149898
Drug: ZYN002
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD.
Study: NCT00612794
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, once weekly
Study: NCT03033589
Drug: Marcaine 0.25 % Injectable Solution
Normalized name: Marcaine 0.25 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
Study: NCT03033589
Drug: Marcaine 0.25 % Injectable Solution
Normalized name: Marcaine 0.25 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
Study: NCT02231307
Drug: SUBLIVAC FIX Birch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01676311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Arm (blinded randomization) for Huperzine A Intervention
Study: NCT03859570
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00572156
Drug: NutropinAq® (Somatropin [rDNA origin])
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (Somatropin) 45µg/kg once daily injection
Study: NCT00572156
Drug: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
Study: NCT00572156
Drug: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
Study: NCT00572156
Drug: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
Study: NCT00195585
Drug: Isovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03716570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04537585
Drug: Vernonia amygdalina
Normalized name: Vernonia appendiculata leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity).